Moberg Pharma launches new Kerasal Nail® line extension in beauty section of CVS, second largest U.S. drug chain

Moberg Pharma AB (OMX: MOB) today announced that it shipped opening orders of
its new line extension, Kerasal Nail® Fungal Nail Repair, to CVS/pharmacy, the
nation’s second largest drug chain. CVS is the first national drug chain to sell
this new item, which is packaged and merchandised specifically for beauty
shoppers.
Kerasal Nail® Fungal Nail Repair will be sold in approxi-mately 5,500 CVS
locations in the nail care aisle of the beauty section of CVS, beginning in
January 2015. Kerasal Nail® continues to be the number one selling SKU in the
foot care section at CVS, where it launched in 2012.

“We are pleased to launch this new line extension at CVS. Kerasal Nail®’s new
beauty focused SKU gives Kerasal Nail® penetration into a completely different
part of the store, where we can target shoppers who don’t visit the foot care
aisle. This opens new possi-bilities to grow the market for nail treatments as
well as to increase our market share. It is consistent with our strategic goal
to be number one in products related to nail fungus,” said Peter Wolpert, CEO of
Moberg Pharma AB.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.30 am(CET) on December 5, 2014.
For additional information contact:
Peter Wolpert, CEO
Telephone: +46 (0)70 - 735 71 35
E-mail: peter.wolpert@mobergpharma.se

Peter Östling, IR
Mobil: +46 (0)76 – 314 09 78
Email: peter.ostling@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
a direct sales and marketing organization in the U.S. and an extensive
distributor network in more than 40 countries. The company’s OTC portfolio
includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®,
and Fergon®. Kerasal Nail® (Nalox™ in certain ex-U.S. markets) is the leading
product for the treatment of nail disorders in the U.S. and Nordic market. The
current portfolio will be supplemented by the acquisition and in-licensing of
additional products as well as product development with a focus on innovative
drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and
New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list
of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please
visit: www.mobergpharma.com.